Clinical trials found that 77% of patients went into remission after receiving obe-cel
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
_256_384.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Subscribe To Our Newsletter & Stay Updated
